CompletedNot Applicable

Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling

Switzerland444 participantsStarted 2018-01-14

Plain-language summary

The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) in hospitalized patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Hospitalized patients at any of the Geneva University Hospitals 18 yo and older * Treated with DOAC (dabigatran, rivaroxaban, apixaban) or/and P2Y12 (clopidogrel, ticragrelor et prasugel) at the time of study blood sampling * Understanding of French language and able to give an inform consent. Exclusion Criteria: * Patients with a reduced life span (\<6 mois) * Exclusion criteria during follow up * Change in dosage or cessation of the DOAC or P2Y12 taken by the participant follow up data will be censored at the time of change.

What they're measuring

Area Under the Curve (AUC)

Timeframe: 2 years

Trial details

NCT IDNCT03477331

SponsorUniversity Hospital, Geneva

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-01-31

View on ClinicalTrials.gov More Cardiovascular Diseases trials